Buflomedil hydrochloride Chemical Properties

Melting point:

192-193°

storage temp. 

Inert atmosphere,Room Temperature

solubility 

Freely soluble in water, soluble in ethanol (96 per cent), very slightly soluble in acetone.

form 

Solid

color 

White to Off-White

InChIKey

ZDPACSAHMZADFZ-UHFFFAOYSA-N

CAS DataBase Reference

35543-24-9(CAS DataBase Reference)

Safety Information

WGK Germany 

3

RTECS 

EL9885000

HS Code 

2933.99.8290

Toxicity

LD50 in mice (mg/kg): 80 ±4.6 i.v. (Lafon)

MSDS

• Language:English Provider:SigmaAldrich

Buflomedil hydrochloride Usage And Synthesis

Description

Buflomedil hydrochloride is a vasoactive drug with a variety of actions. It is an alpha-adrenoceptor antagonist and a weak calcium channel blocker. It inhibits platelet aggregation and improves erythrocyte deformability. However, its mechanism of action in peripheral vascular disease is not known.
Buflomedil has generally been well tolerated by most patients in clinical trials. The most frequently reported adverse effects include flushing, headache, vertigo, gas-trointestinal discomfort, and dizziness. These rarely require drug withdrawal. In controlled trials, adverse effects have occurred in 20% of patients assigned to buflomedil and 18% of those assigned to placebo; only gastrointestinal discomfort occurred more frequently in buflomedil-treated patients (3.4 versus 2%)

Uses

Buflomedil hydrochloride is a vasoactive agent. Its mode of action involves increasing the peripheral and cerebral blood flow in ischaemic tissues of patients, who are mostly affected with vascular diseases.
Buflomedil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in peripheral and cerebral vascular diseases

Biological Activity

Buflomedil is a non-selective antagonist of α-adrenergic receptors (α-ARs) and vasoactive compound.It binds to rat α1A- and α1B-ARs (Kis = 4.06 and 6.84 µM, respectively) and human platelet α2-ARs (IC50 = 1 µM) in radioligand binding assays.Buflomedil (0.06-60 µM) inhibits contraction of isolated canine saphenous veins induced by phenylephrine, clonidine, sympathetic nerve stimulation, or norepinephrine.It inhibits ADP-, collagen-, or epinephrine-induced aggregation of isolated human platelets when used at a concentration of 100 µM.Buflomedil (10 mg/kg) reduces hippocampal neuronal cell death in a rat model of carotid clamping-induced ischemia-reperfusion injury.
https://www.caymanchem.com

Synthesis

The target compound of buflomedil hydrochloride was synthesized from methyl 4-chlorobutyrate by condensation with pyrrolidine,then by hydrolysis,acylation,Fridel-crafts alkylation and salt formation.The structure of the target compound was confirmed by IR,1H-NMR and MS.The synthetic procedure is suitable for industrial production for the advantage of avaible materials,shorter routes,convenient operation and lower cost,the overall yield is improved from the reported 70% to 75.7%.
https://www.semanticscholar.org

Overdosage

Buflomedil is generally considered to be innocuous at therapeutic dosages. Acute toxicity is due to accidental or intentional overdosage. Overdosage causes generalized seizures and cardiac conduction abnormalities, eventually leading to cardiac arrest (SEDA-21, 215).
Meyler's Side Effects of Cardiovascular Drugs

Chemical Properties

White Solid

Originator

Fonzylane,Lafon,France,1976

Uses

1-[3-(2,4,6-Trimethoxybenzoyl)propyl]pyrrolidinium chloride is used as an vasodilator (peripheral).

Manufacturing Process

Introduce 33.6 g (0.2 mol) of 1,3,5-trimethoxybenzene and 100 ml of chlorobenzene into a 500 ml three-neck flask with stirrer, hydrochloric acid bubbler and condenser. Stir to dissolve and add 27.7 g of 4- pyrrolidinobutyronitrile (from 4-chlorobutyronitrile and pyrrolidine). Cool to about 15°-20°C and bubble hydrochloric acid gas in for 4 hours. Cool to about 5°C and add 200 cm3 of water. Stir. Decant the aqueous layer, wash again with 150 cm3 of water. Combine the aqueous layers, drive off the traces of chlorobenzene by distilling 150 cm3 of water, and heat under reflux for one hour. Cool and render alkaline by means of 60 ml of sodium hydroxide solution of 36° Baume. Extract twice with 100 ml of ether. Wash the ether with 100 ml of water. Dry the ether over sodium sulfate and slowly run in 50 ml of 5N hydrogen chloride solution in ether, at the boil. Cool in ice. Filter, wash with ether and dry in a vacuum oven. 33.6 g of crude product are obtained. Recrystallize from 200 ml of isopropanol in the presence of 3 SA carbon black. Filter. Wash and dry in a vacuum oven.
26.9 g of a white, crystalline water-soluble powder are obtained. Yield: 39.2%. Instantaneous melting point: 192°-193°C.

Therapeutic Function

Vasodilator

Buflomedil hydrochloride(35543-24-9)Related Product Information

• Duloxetine hydrochloride
• Difenoconazole
• Centella asiatica extract
• Bumetanide
• Entacapone
• Oxiracetam
• Betahistine dihydrochloride
• Nicotinamide
• Idarubicin hydrochloride
• Gemcitabine hydrochloride
• 5-Diethylamino-2-pentanone
• Pyrrole
• Buflomedil
• 2,4,6-Trimethoxybenzaldehyde
• Buflomedil hydrochloride
• 4-(4-AMINOBUTYL)PHENOL
• 4-(4-METHOXYPHENYL)BUTAN-1-AMINE
• P-DEMETHYLBUFLOMEDIL